跳至主要内容
临床试验/NCT03064906
NCT03064906已完成不适用

Evaluating Meal Performance and Effect of Moderate Intensity Exercise in Patients With Type 1 Diabetes With the Insulet Automated Glucose Control System: IDE 2

Insulet Corporation6 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2017年3月18日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
24
试验地点
6
主要终点
Percentage of time in hypoglycemic range (defined as < 70 mg/dL)

研究概览

简要总结

To assess the safety and performance of the Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm in adults with type 1 diabetes consuming high fat meals and undertaking moderate intensity exercise.

详细描述

The two-part study schedule consists of a 7±1 day outpatient, open-loop phase, followed by one 54-hour, hybrid closed-loop phases conducted in a supervised CRC or hotel/rental house setting.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age at time of consent 18.0 to 65.0 years
  • Diagnosed with type 1 diabetes for at least one year. Diagnosis is based on investigator's clinical judgment.
  • Total daily dose (TDD) of insulin ≥0.3 units/kg/day and A1C >6% at screening
  • Currently using an insulin pump with U-100 rapid-acting insulin analogs and on pump therapy for at least 6 months prior to study start
  • Willing to use the study CGM device for the duration of the study
  • Willing to use the Omnipod® Insulin Management System during the study
  • Willing to perform all fingerstick BG testing with the study-approved glucose meter at the frequency specified in the study protocol
  • Willing to abide by meal recommendations for breakfast, lunch and dinner during the study
  • Willing to participate in moderate intensity exercise for up to 45 minutes if taking part in Option B
  • Willing to refrain from use of acetaminophen and supplemental vitamin C (>2000 mg/daily) for the entire duration of participation in the study
  • Willing and able to sign the Informed Consent Form (ICF)

排除标准

  • A1C >10% at the screening visit
  • One or more episodes of severe hypoglycemia requiring emergency room (ER) visit or hospitalization within the past 6 months
  • Hypoglycemic unawareness as determined by a score of ≥4 "R" responses on the Clarke Questionnaire
  • One or more episodes of diabetic ketoacidosis requiring ER visit or hospitalization within the past 6 months
  • Used non-insulin anti-diabetic medication within last 30 days
  • Pregnant or lactating, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD or implant)
  • Dermatological conditions at the proposed sensor wear sites that in the investigator's opinion could preclude ability to wear the Pod and/or the Dexcom sensor
  • Current or known history of cardiovascular disease, arrhythmia, myocardial infarction (MI) or stroke. An electrocardiogram (ECG) must be obtained within 6 months.
  • Currently undergoing systemic treatment with steroids or immunosuppressive medication
  • Current illness that would interfere with participation in the study
  • Currently participating in another clinical study using an investigational drug or device
  • Recent (within the preceding 30 days) participation in a clinical study using an investigational drug.

研究组 & 干预措施

Meal Performance and/or Exercise

Other

This study is a two-part, multi-center, observational clinical trial being conducted in a Clinical Research Center (CRC) setting using the Insulet AP (artificial pancreas) system.

Subjects may participate in hybrid closed-loop session Option A - Meal Performance and/or Option B - Exercise, but are not required to participate in both. If participating in both, Option A and Option B must be conducted in separate sessions.

干预措施: Insulet AP (artificial pancreas) System (Device)

结局指标

主要结局

Percentage of time in hypoglycemic range (defined as < 70 mg/dL)

时间窗: 54 hours

Percentage of time in hyperglycemic range(defined as ≥ 250 mg/dL)

时间窗: 54 hours

次要结局

  • Percentage of time < 50 mg/dL(54 hours)
  • Percentage of time between 70-180 mg/dL(54 hours)
  • Meal challenge-12 hour PPG dinner(54 hours)
  • Percentage of time between 70-140 mg/dL(54 hours)
  • Meal challenge-4 hour PPG breakfast(54 hours)
  • Exercise challenge-immediate and delayed glucose response(54 hour)
  • Mean glucose(54 hours)
  • Percentage of time < 60 mg/dL(54 hours)
  • Effect of changing setpoints(54 hour)
  • Percentage of time > 180 mg/dL(54 hours)
  • Percentage of time ≥ 300 mg/dL(54 hours)
  • Standard deviation(54 hours)
  • Coefficient of variation(54 hours)
  • Meal challenge-4 hour PPG lunch(54 hour)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (6)

Loading locations...

相似试验

Insulet Artificial Pancreas Evaluating Meal... | 临床试验